{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:00Z","timestamp":1792012320451,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Advisory board to DISC Medicine and Agios; AT and NG are members of the editorial board for BCJ."},{"name":"Research funding from Novartis, BMS, Solu Therapeutics and Sanofi"},{"name":": BeiGene Shanghai, Amgen,Astellas Pharma, Actinium Pharmaceuticals, Syndax, Consultancy;"},{"name":"Research funding from Kura Oncology, Stemline therapeutics, Epigenetix, Solutherapeutics, Polaris and has served on the advisory board for AstraZeneca and SOBI pharmaceuticals"},{"name":"Curio Science, Consultancy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01495-x","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:08:24Z","timestamp":1775459304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-7923","authenticated-orcid":false,"given":"Saubia","family":"Fathima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-3341","authenticated-orcid":false,"given":"Lior","family":"Rokach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Ghosoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Rezasoltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimal","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alsugair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2619","authenticated-orcid":false,"given":"Kristen","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maymona","family":"Abdelmagid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasiya","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7336","authenticated-orcid":false,"given":"Antoine N.","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-3380","authenticated-orcid":false,"given":"Mehrdad","family":"Hefazi Torghabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-1708","authenticated-orcid":false,"given":"James","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sproat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Arana Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"1495_CR1","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481\u2013e491.","journal-title":"Lancet Haematol"},{"key":"1495_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14:163.","journal-title":"Blood Cancer J"},{"key":"1495_CR3","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","volume":"25","author":"AC Krauss","year":"2019","unstructured":"Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W, et al. FDA Approval Summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res. 2019;25:2685\u201390.","journal-title":"Clin Cancer Res"},{"key":"1495_CR4","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","volume":"34","author":"W-S Lim","year":"2010","unstructured":"Lim W-S, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34:1214\u201323.","journal-title":"Leuk Res"},{"key":"1495_CR5","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"1495_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1495_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99:193\u2013202.","journal-title":"Am J Hematol"},{"key":"1495_CR8","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6:3997\u20134005.","journal-title":"Blood Adv"},{"key":"1495_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ajcp\/aqab172","volume":"157","author":"Y Gao","year":"2022","unstructured":"Gao Y, Jia M, Mao Y, Cai H, Jiang X, Cao X, et al. Distinct mutation landscapes between acute myeloid leukemia with myelodysplasia-related changes and de novo acute myeloid leukemia. Am J Clin Pathol. 2022;157:691\u2013700.","journal-title":"Am J Clin Pathol"},{"key":"1495_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/ajcp\/aqz206","volume":"153","author":"H Fang","year":"2020","unstructured":"Fang H, He R, Chiu A, Viswanatha DS, Ketterling RP, Patnaik MS, et al. Genetic factors in acute myeloid leukemia with myelodysplasia-related changes. Am J Clin Pathol. 2020;153:656\u201363.","journal-title":"Am J Clin Pathol"},{"key":"1495_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1495_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1495_CR13","first-page":"150","volume":"20","author":"Rudin BUaC","year":"2019","unstructured":"BUaC Rudin. Learning optimized risk scores. J Mach Learn Res. 2019;20:150 1\u201375, 2019.","journal-title":"J Mach Learn Res"},{"key":"1495_CR14","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s10994-021-06117-0","volume":"111","author":"D Bertsimas","year":"2022","unstructured":"Bertsimas D, Dunn J, Gibson E, Orfanoudaki A. Optimal survival trees. Mach Learn. 2022;111:2951\u20133023.","journal-title":"Mach Learn"},{"key":"1495_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328.","journal-title":"Lancet Oncol"},{"key":"1495_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2024-200413","volume":"144","author":"SO Shimony","year":"2024","unstructured":"Shimony SO, Murdock H, Keating J, Reilly CR, Tsai HK, Gibson CJ, et al. AML-MR mutations drive the benefit of CPX-351 over 7+3 in the pivotal phase 3 AML trial. Blood. 2024;144:60.","journal-title":"Blood"},{"key":"1495_CR17","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1182\/bloodadvances.2021006468","volume":"6","author":"GL Uy","year":"2022","unstructured":"Uy GL, Newell LF, Lin TL, Goldberg SL, Wieduwilt MJ, Ryan RJ, et al. Transplant outcomes after CPX-351 vs 7\u2009+\u20093 in older adults with newly diagnosed high-risk and\/or secondary AML. Blood Adv. 2022;6:4989\u201393.","journal-title":"Blood Adv"},{"key":"1495_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J. 2025;15:139.","journal-title":"Blood Cancer J"},{"key":"1495_CR19","doi-asserted-by":"publisher","first-page":"E196","DOI":"10.1002\/ajh.26157","volume":"96","author":"A Salhotra","year":"2021","unstructured":"Salhotra A, Aribi A, Ngo D, Zhang J, Sandhu K, Al-Malki M, et al. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351). Am J Hematol. 2021;96:E196\u2013E200.","journal-title":"Am J Hematol"},{"key":"1495_CR20","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","volume":"38","author":"S Shimony","year":"2024","unstructured":"Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, et al. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 2024;38:762\u20138.","journal-title":"Leukemia"},{"key":"1495_CR21","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood.2024027217","volume":"145","author":"J Lu","year":"2025","unstructured":"Lu J, Xue S-l, Wang Y, He X-f, Hu X-h, Miao M, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood. 2025;145:2645\u201355.","journal-title":"Blood"},{"key":"1495_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","volume":"5","author":"E Chiche","year":"2021","unstructured":"Chiche E, Rahm\u00e9 R, Bertoli S, Dumas PY, Micol JB, Hicheri Y, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176\u201384.","journal-title":"Blood Adv"},{"key":"1495_CR23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/ajh.27730","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A. CPX-351 (Vyxeos) in acute myeloid leukemia: time to move on? Am J Hematol. 2025;100:1271\u20136.","journal-title":"Am J Hematol"},{"key":"1495_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35846","volume":"131","author":"MR Khouri","year":"2025","unstructured":"Khouri MR, Wang B, Pearson LK, Gillis-Smith AJ, Suzuki S, Hutchinson LM, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 2025;131:e35846.","journal-title":"Cancer"},{"key":"1495_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2025-6","volume":"146","author":"A Fathi","year":"2025","unstructured":"Fathi A, Perl A, Fell G, Jonas B, Ragon B, Mims A, et al. Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. 2025;146:6\u20136.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01495-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01495-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01495-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:03:20Z","timestamp":1779206600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01495-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1495"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01495-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SF: Nothing to disclose; LR: Nothing to disclose; NoG: Nothing to disclose; MR: Nothing to disclose; RI: Nothing to disclose; AA: Nothing to disclose; KM: Nothing to disclose; MA: Nothing to disclose; AAK: Nothing to disclose; HBA: Nothing to disclose; KHB: Nothing to disclose; AAM: Research funding from Novartis, BMS, Solu Therapeutics and Sanofi; AM: Nothing to disclose; ANS: Nothing to disclose; MHT: Nothing to disclose; MRL: BeiGene Shanghai, Amgen,Astellas Pharma, Actinium Pharmaceuticals, Syndax, Consultancy; WH: Nothing to disclose; MS: Nothing to disclose; MMP: Research funding from Kura Oncology, Stemline therapeutics, Epigenetix, Solutherapeutics, Polaris and has served on the advisory board for AstraZeneca and SOBI pharmaceuticals, AP: Nothing to disclose; TB: Nothing to disclose; HM: Nothing to disclose; JF: Nothing to disclose; JP: Nothing to disclose; NP: Nothing to disclose; LS: Nothing to disclose; NK: Nothing to disclose; CAY: Curio Science, Consultancy; AT: Nothing to disclose; NG: Advisory board to DISC Medicine and Agios; AT and NG are members of the editorial board for BCJ.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the Mayo Clinic (IRB protocol number: 12-003574). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"78"}}